Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
View Older Stories View More Recent Stories
-
Bernstein: 'Royal Caribbean Cruises (RCL) Best Protected, CCL Worst'
-
Bernstein Reiterates Market Perform Rating on Cintas (CTAS)
-
ASML Inc. (ASML) PT Raised to $1,971; Bernstein: 'This brings significant growth to ASML'
-
Pinduoduo Inc. (PDD) PT Lowered to $132 at Bernstein
-
Bernstein downgrades Qualcomm, says investors 'can buy actual AI winners'
-
Bernstein SocGen Group Downgrades Qualcomm (QCOM) to Market Perform
-
Crypto News: Pepeto Announces Capital Update While Bernstein Bitcoin Price Prediction Targets $150,000 And Altcoin Rotation Builds
-
Crypto News: Pepeto Presale Staking Update While Bitcoin Whales Stack 270,000 BTC and Now Target Meme Coin Presales
-
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds
-
Bernstein flags this defensive stock in the current macro uncertainty
-
TBL Team Boxing League Announces Hall of Fame Broadcaster Al Bernstein Joins as Lead Analyst
-
Bernstein sees 1970s-style supercycle for Middle East oil services
-
Bernstein Reiterates Market Perform Rating on Tyson (TSN)
-
Hesai Group (HSAI) PT Lowered to $32 at Bernstein SocGen Group
-
Bernstein on Dollarama Inc. (DOL:CN) (DLMAF): 'Recent pullback provides a more attractive entry point'
-
Dollar General (DG) PT Lowered to $146 at Bernstein Amid CEO Transition
-
Frequency Electronics Inc. Announces Space Mission Contract Award Valued at Approximately $7 million
-
Maze Therapeutics reports positive Phase 2 trial data for kidney drug
-
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
-
New Clinical Frontiers for Acclaro's UltraClear® 2910 nm Fiber Laser Revealed by Leading Experts at the American Academy of Dermatology Annual Meeting
-
S2 CAPITAL MAKES STRATEGIC PUSH INTO THE ATLANTA INDUSTRIAL MARKET WITH SENIOR HIRE
-
Bitcoin bottom likely in, upside ahead: Bernstein
-
Bernstein SocGen Group Starts NTPC Green Energy (NTPCGREE:IN) at Underperform
-
Bernstein SocGen Group Starts Tata Power (TPWR:IN) at Outperform
-
Bernstein SocGen Group Starts JSW Energy Ltd (JSW:IN) at Outperform
-
Bernstein SocGen Group Starts Adani Power Limited (ADANI:IN) at Outperform
-
Bernstein Reiterates Market Perform Rating on Southwest (LUV)
-
Bernstein on Gilead Sciences (GILD) Amid Ouro Acquisition
-
Bernstein: 'Bitcoin Looks Bottomed, Strategy (MSTR) Remains Resilient'
-
Bernstein Reiterates Underperform Rating on CoreWeave (CRWV)
-
McCormick & Company (MKC) PT Lowered at Bernstein Amid Potential Reverse Morris Trust Deal
-
Minimus Launches Open Source Program, Bringing Hardened Images to Critical Infrastructure Projects
-
SK Hynix to buy $8 billion in ASML chipmaking tools in largest disclosed order
-
This crypto stocks is the best proxy for stablecoin upside
-
This U.S. natural gas stock is a new Top Pick at Bernstein
-
Motor racing-F1 owner Liberty Media can ride out Mideast conflict
-
Bernstein: 'Own Both NVDA and AVGO'
-
Bernstein Thoughts on Super Micro Computer (SMCI) Amid Smuggling Charges
-
Bernstein Reorders Americas Oil & Gas Stock Rankings and Highlights Top Ideas
-
Kosmos Energy (KOS:LN) (KOS) PT Raised to GBP0.83 at Bernstein SocGen Group
-
Bernstein Shares Highlights from the Ermenegildo Zegna Group (ZGN) FY25 Conference Call
-
XPeng (XPEV) PT Raised to $22 at Bernstein As 'Q4 Delivers First Profit'
-
DELL, HPQ, or HPE: Which IT hardware stock to buy in 2026
-
Form 4 Maze Therapeutics, Inc. For: Mar 20 Filed by: Bernstein Harold
-
Bernstein SocGen Group Starts Immunovant (IMVT) at Market Perform
-
Bernstein SocGen Group Starts Roivant Sciences (ROIV) at Outperform
-
FedEx (FDX) PT Raised to $466 at Bernstein SocGen Group
-
Bernstein SocGen: 'unique opportunity for Apple to gain share in both smartphones and PCs'
-
Bernstein on SMCI (SMCI): 'Do we need to add a smuggling line to our SMCI revenue build?'
-
These are the best EU pharma stocks to buy: analyst

